<DOC>
	<DOCNO>NCT02172391</DOCNO>
	<brief_summary>Trial investigate acute chronic effect tiotropium therapy airway diameter COPD patient measure inspiratory capacity ( IC ) .</brief_summary>
	<brief_title>Effect Tiotropium Airway Diameter Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>All patient must diagnosis chronic obstructive pulmonary disease Male female patient ≥ 40 year age ≤ 75 year old Patients must smoke history ten packyears . A packyear defined equivalent smoke one pack cigarettes per day year Patients must able perform specify procedure maintain record study period require protocol Patients must able inhale medication HandiHaler® All patient must sign Patient Informed Consent Form prior participation trial i.e. , prior prestudy washout usual pulmonary medication Patients must willing attend outpatient clinic regular basis Patients must able walk 164 foot ( 50 meter ) Six Minute Walk Test Patients significant disease COPD exclude . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study Patients clinically significant abnormal baseline haematology , blood chemistry urinalysis test result , abnormality defines disease list exclusion criterion Patients serum glutamicoxaloacetic transaminase ( SGOT ) ≥1.5 x Upper Limit Normal Range ( ULN ) , serum glutamicpyruvic transaminase ( SGPT ) ≥1.5 x ULN , bilirubin ≥1.5 x ULN creatinine ≥ 1.5 x ULN regardless clinical condition Patients recent history ( i.e. , one year less ) myocardial infarction Patients recent history ( i.e. , three year less ) heart failure , pulmonary edema patient cardiac arrhythmia ( without symptom ) Patients regular use daytime oxygen therapy Patients know active tuberculosis Patients history cancer within last five year . Patients treat basal cell carcinoma allow Patients history lifethreatening pulmonary obstruction , history cystic fibrosis bronchiectasis Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion . 1 Patients upper respiratory tract infection past six week prior Screening Visit baseline period Patients know hypersensitivity anticholinergic drug , lactose component inhalation capsule delivery system Patients know symptomatic prostatic hypertrophy bladder neck obstruction Patients know narrowangle glaucoma Patients treat cromolyn sodium nedocromil sodium Patients treat antihistamine ( H1 receptor antagonist ) antileukotrienes able stop medication 1 month visit 1 Patients use oral corticosteroid medication unstable dos ( i.e. , less six week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day Pregnant nursing woman woman childbearing potential use medically approve mean contraception Patients history asthma , allergic rhinitis atopy total blood eosinophil count ≥ 600/mm3 Patients history ( past five year less ) and/or active alcohol drug abuse Patients take investigational drug within one month six half life ( whichever great ) prior Screening Period ( Visit 1 ) Patients participate pulmonary rehabilitation program COPD within 6 week prior Visit 1 throughout study Limitation exercise performance result factor fatigue exertional dyspnea arthritis leg , angina claudication</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>